ACTR-70. IMPACT OF BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND POOR PERFORMANCE STATUS

Clinical trials have showed that bevacizumab is beneficial for patients with recurrent glioblastoma and partially effective against newly diagnosed glioblastoma. However, glioblastoma patients with poor performance status (PS) were excluded from these clinical trials, and the efficacy of bevacizumab...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Furuse, Motomasa, Kawabata, Shinji, Ikeda, Naokado, Nonoguchi, Naosuke, Tamura, Yoji, Kajimoto, Yoshinaga, Miyatake, Shin-Ichi, Kuroiwa, Toshihiko
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693094/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.057
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki